Research programme: epilepsy and essential tremor therapeutics - OB Pharmaceuticals
Latest Information Update: 28 Feb 2023
At a glance
- Originator University of Ottawa
- Developer OB Pharmaceuticals
- Class Antiepileptic drugs
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Essential tremor
- No development reported Epilepsy
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Epilepsy in Canada
- 06 Jul 2021 Epilepsy and essential tremor therapeutics are available for licensing as of 06 Jul 2021. https://www.obpharmaceuticals.com/investors-2/ (OB Pharmaceuticals website, July 2021)
- 06 Jul 2021 Preclinical trials in Essential tremor in Canada (unspecified route) before July 2021 (OB Pharmaceuticals website, July 2021)